New drug shows promise for slowing kidney disease in IgA nephropathy
NCT ID NCT04716231
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests atacicept, a weekly injection, in 376 adults with IgA nephropathy (Berger's disease). The goal is to reduce protein in the urine and slow the loss of kidney function. Participants receive either atacicept or a placebo for about a year. The study is active but no longer recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- atacicept
- What this could lead to
- If it works, this could provide a new treatment option to slow kidney damage in people with IgA nephropathy.
- What could go wrong
- This is a late-stage trial, but results are not yet final. The drug may not prove effective enough or could have side effects. It is not a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BERGER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ORIGIN 3 Global Site Contact Information
Brisbane, California, 94005, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Mapping the Real-World treatment landscape for IgA nephropathy
- A simple test could forecast kidney disease progression
- Experimental drug aims to protect kidneys in inflammatory diseases
- Scientists probe kidney cell metabolism to unlock secrets of ANCA vasculitis
- Atacicept's Long-Term promise for kidney disease
- Immune cell therapy takes on kidney disease